Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients

C. Resteghini, S. Cavalieri, D. Galbiati, R. Granata, S. Alfieri, C. Bergamini, P. Bossi, L. Licitra, L. D. Locati

Research output: Contribution to journalReview article

Abstract

Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC. Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials. The toxicity burden associated to TKIs is not negligible. Drug reductions and interruptions are common, definitive drug withdrawals have also been reported as well as toxic deaths in more rare cases. In this context, the prevention of toxicities is mandatory to allow patients to stay on treatment as long as possible without dose and schedule modifications. Both physicians and patients should be educated to recognize drug-related toxicities in order to manage them in an early phase. Tools (e.g. toxicities summary booklet) for physicians and patients could be considered to improve the knowledge on side effects management. Guidelines, whenever available, should be followed.

Original languageEnglish
Pages (from-to)349-361
Number of pages13
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume31
Issue number3
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Protein-Tyrosine Kinases
Thyroid Neoplasms
Physicians
Pamphlets
Poisons
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Appointments and Schedules
Guidelines
Medullary Thyroid cancer
Therapeutics
axitinib
lenvatinib
pazopanib
sorafenib
cabozantinib
sunitinib
N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine

Keywords

  • gastrointestinal
  • hypertension
  • management
  • thyroid carcinoma
  • TKI
  • toxicity

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. / Resteghini, C.; Cavalieri, S.; Galbiati, D.; Granata, R.; Alfieri, S.; Bergamini, C.; Bossi, P.; Licitra, L.; Locati, L. D.

In: Best Practice and Research: Clinical Endocrinology and Metabolism, Vol. 31, No. 3, 01.06.2017, p. 349-361.

Research output: Contribution to journalReview article

@article{78d64a57d4124b5b863690a89c5decda,
title = "Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients",
abstract = "Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC. Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials. The toxicity burden associated to TKIs is not negligible. Drug reductions and interruptions are common, definitive drug withdrawals have also been reported as well as toxic deaths in more rare cases. In this context, the prevention of toxicities is mandatory to allow patients to stay on treatment as long as possible without dose and schedule modifications. Both physicians and patients should be educated to recognize drug-related toxicities in order to manage them in an early phase. Tools (e.g. toxicities summary booklet) for physicians and patients could be considered to improve the knowledge on side effects management. Guidelines, whenever available, should be followed.",
keywords = "gastrointestinal, hypertension, management, thyroid carcinoma, TKI, toxicity",
author = "C. Resteghini and S. Cavalieri and D. Galbiati and R. Granata and S. Alfieri and C. Bergamini and P. Bossi and L. Licitra and Locati, {L. D.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.beem.2017.04.012",
language = "English",
volume = "31",
pages = "349--361",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

TY - JOUR

T1 - Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients

AU - Resteghini, C.

AU - Cavalieri, S.

AU - Galbiati, D.

AU - Granata, R.

AU - Alfieri, S.

AU - Bergamini, C.

AU - Bossi, P.

AU - Licitra, L.

AU - Locati, L. D.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC. Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials. The toxicity burden associated to TKIs is not negligible. Drug reductions and interruptions are common, definitive drug withdrawals have also been reported as well as toxic deaths in more rare cases. In this context, the prevention of toxicities is mandatory to allow patients to stay on treatment as long as possible without dose and schedule modifications. Both physicians and patients should be educated to recognize drug-related toxicities in order to manage them in an early phase. Tools (e.g. toxicities summary booklet) for physicians and patients could be considered to improve the knowledge on side effects management. Guidelines, whenever available, should be followed.

AB - Four tyrosine kinase inhibitors (TKIs) have been recently licensed in thyroid cancer (TC), sorafenib and lenvatinib for differentiated TC, vandetanib and cabozantinib for medullary TC. Others TKIs such as axitinib, pazopanib, sunitinib, have been tested within phase II trials. The toxicity burden associated to TKIs is not negligible. Drug reductions and interruptions are common, definitive drug withdrawals have also been reported as well as toxic deaths in more rare cases. In this context, the prevention of toxicities is mandatory to allow patients to stay on treatment as long as possible without dose and schedule modifications. Both physicians and patients should be educated to recognize drug-related toxicities in order to manage them in an early phase. Tools (e.g. toxicities summary booklet) for physicians and patients could be considered to improve the knowledge on side effects management. Guidelines, whenever available, should be followed.

KW - gastrointestinal

KW - hypertension

KW - management

KW - thyroid carcinoma

KW - TKI

KW - toxicity

UR - http://www.scopus.com/inward/record.url?scp=85019553867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019553867&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2017.04.012

DO - 10.1016/j.beem.2017.04.012

M3 - Review article

AN - SCOPUS:85019553867

VL - 31

SP - 349

EP - 361

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 3

ER -